|drug65||Allogenic pooled olfactory mucosa-derived mesenchymal stem cells Wiki||1.00|
|D017563||Lung Diseases, Interstitial NIH||0.41|
|D011024||Pneumonia, Viral NIH||0.14|
There is one clinical trial.
Treatment of patients with Covid-19 associated pneumonia using intravenous injection of allogenic pooled olfactory mucosa-derived mesenchymal stem cells
Description: Number of patients cured, assessed by PCR in addition to chest CT scanMeasure: Number of cured patients Time: 3 weeks
Description: MSC infusion related adverse events assessed by blood count, liver and function testsMeasure: Number of patients with treatment-related adverse events Time: 3 weeks